RedHill Biopharma (RDHL) Invested Capital (2022 - 2024)

RedHill Biopharma (RDHL) has disclosed Invested Capital for 3 consecutive years, with $7.3 million as the latest value for Q4 2024.

  • Quarterly Invested Capital fell 37.05% to $7.3 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $7.3 million through Dec 2024, down 37.05% year-over-year, with the annual reading at $7.3 million for FY2024, 37.05% down from the prior year.
  • Invested Capital for Q4 2024 was $7.3 million at RedHill Biopharma, down from $11.7 million in the prior quarter.
  • The five-year high for Invested Capital was $11.7 million in Q4 2023, with the low at -$37.2 million in Q4 2022.
  • Average Invested Capital over 3 years is -$6.1 million, with a median of $7.3 million recorded in 2024.
  • The sharpest move saw Invested Capital skyrocketed 131.29% in 2023, then crashed 37.05% in 2024.
  • Over 3 years, Invested Capital stood at -$37.2 million in 2022, then skyrocketed by 131.29% to $11.7 million in 2023, then plummeted by 37.05% to $7.3 million in 2024.
  • According to Business Quant data, Invested Capital over the past three periods came in at $7.3 million, $11.7 million, and -$37.2 million for Q4 2024, Q4 2023, and Q4 2022 respectively.